Neptune Technologies & Bioressources Inc. to Host Management Discussion Teleconference at 9:00 a.m. on January 14th
13 January 2011 - 3:26AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) will host a management discussion on the
three and nine-month periods ended November 30, 2010 ("Q3")
financial results in a teleconference on Friday January 14th at
9:00 a.m. Eastern Standard Time ("EST").
Neptune will release its Q3 financial results after market close
on Thursday, January 13th, 2011. The results will be discussed
prior to market open the following morning in a teleconference
hosted by Andre Godin, Vice-President, Administration &
Finance.
Teleconference details are as
follows: |
|
Friday, January 14, 2011, 9:00 AM (EST) |
|
Participant Dial-In Number(s): |
Operator Assisted Toll-Free Dial-In Number:
1-888-241-0394 |
International Dial-In #:
+1-647-427-3413 |
|
Conference ID # 36980243 |
TO SUBMIT EMAIL QUESTIONS BEFORE OR DURING THE
TELECONFERENCE SEND AN EMAIL TO:
x.harland@neptunebiotech.com
Please refer to the management discussion teleconference.
The recording will be available within 2 hours of the event by
dialing 1 (800) 642-1687 or (706) 645-9291. The archive can be
accessed until January 28th.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Acasti Contact
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
Howard Group Contact:
Bob Beaty
1 (888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024